Cargando…
Cross-suppression of EGFR ligands amphiregulin and epiregulin and de-repression of FGFR3 signalling contribute to cetuximab resistance in wild-type KRAS tumour cells
BACKGROUND: In addition to the mutational status of KRAS, the epidermal growth factor receptor (EGFR) ligands amphiregulin (AREG) and epiregulin (EREG) might function as bona fide biomarkers of cetuximab (Ctx) sensitivity for most EGFR-driven carcinomas. METHODS: Lentivirus-delivered small hairpin R...
Autores principales: | Oliveras-Ferraros, C, Cufí, S, Queralt, B, Vazquez-Martin, A, Martin-Castillo, B, de Llorens, R, Bosch-Barrera, J, Brunet, J, Menendez, J A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3326676/ https://www.ncbi.nlm.nih.gov/pubmed/22491422 http://dx.doi.org/10.1038/bjc.2012.103 |
Ejemplares similares
-
Stress-Induced Neuroprotective Effects of Epiregulin and Amphiregulin
por: Zhan, Libin, et al.
Publicado: (2015) -
Amphiregulin and Epiregulin mRNA expression in primary colorectal cancer and corresponding liver metastases
por: Kuramochi, Hidekazu, et al.
Publicado: (2012) -
Prognostic value of amphiregulin and epiregulin mRNA expression in metastatic colorectal cancer patients
por: Jing, Chen, et al.
Publicado: (2016) -
Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer
por: Queralt, Bernardo, et al.
Publicado: (2016) -
Metformin-induced preferential killing of breast cancer initiating CD44(+)CD24(−/low) cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts
por: Cufí, Sílvia, et al.
Publicado: (2012)